Amgen Inc. Canadian Depositary Receipt

Amgen Inc. Canadian Depositary Receipt represents a financial instrument designed to provide investors with convenient access to the shares of Amgen Inc., a leading global biotechnology company, through the use of depositary receipts. These receipts are denominated in Canadian Dollars and feature a built-in currency hedge, minimizing the impact of foreign exchange fluctuations for non-U.S. investors. Amgen is notable for its research, development, and delivery of innovative human therapeutics targeting areas such as inflammation, oncology/hematology, and bone health. By offering exposure to Amgen in fractional share increments, this Canadian Depositary Receipt enhances affordability and accessibility for a broader range of investors. The product holds particular significance for those seeking diversified exposure to the healthcare and biotechnology sectors without the complexities of cross-border transactions or direct foreign currency exposure. Through this structure, the Amgen Inc. Canadian Depositary Receipt plays a vital role in connecting Canadian and European investors to a major player in global healthcare innovation.